Pelthos Therapeutics Inc. (PTHS) stock
PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.84−0.31 (-4.34%)
Close on Nov 17, 2026Market cap $26.19MP/E –Yield –
Earnings
Pelthos Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 18, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$15.40M
EPS, Q3 FY2026
-$2.04
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Pelthos Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 18, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026before the open | $15.40M | – | -$2.04 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026before the open | $15.60M | – | -$6.62 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026before the open | $10.91M | – | -$3.09 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 19, 2026before the open | $9.39M | – | -$6.87 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 18, 2025before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Pelthos Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Pelthos Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Pelthos Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Update
- Update
See a number that looks wrong?